Second-generation antipsychotic discontinuation in first episode psychosis: An updated review

Clinical Psychopharmacology and Neuroscience

Volumn 9, Issue 2, 2011, Pages 45-53

  Miller, Brian J ^a   Bodenheimer, Chelsea ^a   Crittenden, Krystle ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antipsychotic agents; Epidemiology; Patient nonadherence; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ASTHENIA; CONCENTRATION LOSS; CONVALESCENCE; DECISION MAKING; DEPRESSION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; INTERVENTION STUDY; MEDICAL LITERATURE; MENTAL DISEASE; METABOLISM; MONITORING; MORBIDITY; OUTCOME ASSESSMENT; PREVALENCE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RELAPSE; REMISSION; REVIEW; SALIVATION; SCHIZOPHRENIA; SEDATION; SELF REPORT; SIDE EFFECT; SLEEP; SOMATOFORM DISORDER; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 80052594643     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: 10.9758/cpn.2011.9.2.45     Document Type: Review

References (31)

1. Green A.I., Lieberman J.A., Hamer R.M., Glick I.D., Gur R.E., Kahn R.S., et al. Olanzapine and haloperidol in first episode psychosis: Two-year data. Schizophr Res 2006;86:234-243. (Pubitemid 44251272)
2. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-1060. (Pubitemid 47121394)
3. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008;371:1085-1097. (Pubitemid 351418005)
4. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. (Pubitemid 41345943)
5. Miller B.J. A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract 2008;14:289-300.
6. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
7. Moore T.A., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-1762. (Pubitemid 350247505)
8. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28:995-1003.
9. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 2005;162:947-953. (Pubitemid 40676208)
10. Andersen R., Fagerlund B., Rasmussen H., Ebdrup B.H., Aggernaes B., Gade A., et al. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. Psychiatry Res 2011;187:49-54.
11. Berger G.E., Proffitt T.M., McConchie M., Kerr M., Markulev C., Yuen H.P., et al. Dosing quetiapine in drug-naive first-episode psychosis: A controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry 2008;69:1702-1714.
12. Emsley R., Oosthuizen P., Koen L., Niehaus D.J., Medori R., Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection. Int Clin Psychopharmacol 2008;23:325-331.
13. Möller H.J., Riedel M., Jäger M., Wickelmaier F., Maier W., Kühn K.U., et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008;11:985-997.
14. Takahashi H., Oshimo T., Ishigooka J. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: An open-label trial. Clin Neuropharmacol 2009;32:149-150.
15. Cuesta M.J., Jalón E.G., Campos M.S., Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009;194:439-445.
16. Gafoor R., Landau S., Craig T.K., Elanjithara T., Power P., McGuire P. Esquire trial: Efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. J Clin Psychopharmacol 2010;30:600-606.
17. Kim B., Lee S.H., Choi T.K., Suh S., Kim Y.W., Lee E., et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1231-1235.
18. Weiden P.J., Schooler N.R., Weedon J.C., Elmouchtari A., Sunakawa A., Goldfinger S.M. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome. J Clin Psychiatry 2009;70:1397-1406.
19. Gaebel W., Riesbeck M., Von Wilmsdorff M., Burns T., Derks E.M., Kahn R.S., et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol 2010;20:310-316.
20. Malla A., Norman R., Schmitz N., Manchanda R., Béchard-Evans L., Takhar J., et al. Predictors of rate and time to remission in first-episode psychosis: A two-year outcome study. Psychol Med 2006;36:649-658.
21. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-113. (Pubitemid 351282003)
22. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247. (Pubitemid 29125132)
23. Rabiner C.J., Wegner J.T., Kane J.M. Outcome study of first-episode psychosis. I: Relapse rates after 1 year. Am J Psychiatry 1986;143:1155-1158. (Pubitemid 16041886)
24. Gitlin M., Nuechterlein K., Subotnik K.L., Ventura J., Mintz J., Fogelson D.L., et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-1842. (Pubitemid 33054776)
25. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., et al. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897. (Pubitemid 34023591)
26. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549. (Pubitemid 29162974)
27. Bachmann S., Bottmer C., Schroder J. One-year outcome and its prediction in first-episode schizophrenia-a naturalistic study. Psychopathology 2008;41:115-123. (Pubitemid 350308312)
28. Gleeson J.F., Alvarez-Jimenez M., Cotton S.M., Parker A.G., Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res 2010;119:79-88.
29. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56.
30. Wang C.Y., Xiang Y.T., Cai Z.J., Weng Y.Z., Bo Q.J., Zhao J.P., et al. Risperidone maintenance treatment in schizophrenia: A randomized, controlled trial. Am J Psychiatry 2010;167:676-685.
31. Wunderink L., Nienhuis F.J., Sytema S., Slooff C.J., Knegtering R., Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: Relapse rates and functional outcome. J Clin Psychiatry 2007;68:654-661.